Abstract
MUTYH Associated Polyposis (MAP), a Polyposis predisposition caused by biallelic mutations in the Base Excision Repair (BER) gene MUTYH, confers a marked risk of colorectal cancer (CRC). The MAP phenotype is difficult to distinguish from other hereditary CRC syndromes. Especially from Familial Adenomatous Polyposis (FAP) and to a lesser extend Lynch Syndrome, which are caused by germline mutations in the APC and Mismatch Repair (MMR) genes, respectively. Here we review research findings regarding MUTYH interactions, genotypic and phenotypic characteristics of MAP, as well as surveillance and treatment of the disease. The applied papers, published between 1/1 2002- 1/2 2008, were found through PubMed. The exact role of MUTYH in CRC tumorgenesis is still uncertain, although MAP tumors show distinct molecular features, including somatic G:C > T:A transversions in the APC gene. Furthermore, cooperation between the BER and the MMR systems exists, as MUTYH interacts with MMR gene-products. Possibly, monoallelic defects in both pathways are of significance to CRC development. Specific MUTYH variants are found to be characteristic in distinct ethnic populations, which could facilitate future genetic screening. Knowledge concerning functional consequences of many MUTYH germline mutations remains sparse. Most thoroughly investigated are the two most common MUTYH variants, Y179C and G396D, both generating dysfunctional gene products. Phenotypic features of MAP include: development of 10-100 colorectal adenomas, debuting at 46-47 years, often CRC at time of clinical diagnosis, and in some, development of extracolonic manifestations.
Keywords: Colorectal cancer, MUTYH associated polyposis, The MUTYH gene, base excision repair, familial adenomatous polyposis, lynch syndrome
Current Genomics
Title: MUTYH Associated Polyposis (MAP)
Volume: 9 Issue: 6
Author(s): M. L.M. Poulsen and M. L. Bisgaard
Affiliation:
Keywords: Colorectal cancer, MUTYH associated polyposis, The MUTYH gene, base excision repair, familial adenomatous polyposis, lynch syndrome
Abstract: MUTYH Associated Polyposis (MAP), a Polyposis predisposition caused by biallelic mutations in the Base Excision Repair (BER) gene MUTYH, confers a marked risk of colorectal cancer (CRC). The MAP phenotype is difficult to distinguish from other hereditary CRC syndromes. Especially from Familial Adenomatous Polyposis (FAP) and to a lesser extend Lynch Syndrome, which are caused by germline mutations in the APC and Mismatch Repair (MMR) genes, respectively. Here we review research findings regarding MUTYH interactions, genotypic and phenotypic characteristics of MAP, as well as surveillance and treatment of the disease. The applied papers, published between 1/1 2002- 1/2 2008, were found through PubMed. The exact role of MUTYH in CRC tumorgenesis is still uncertain, although MAP tumors show distinct molecular features, including somatic G:C > T:A transversions in the APC gene. Furthermore, cooperation between the BER and the MMR systems exists, as MUTYH interacts with MMR gene-products. Possibly, monoallelic defects in both pathways are of significance to CRC development. Specific MUTYH variants are found to be characteristic in distinct ethnic populations, which could facilitate future genetic screening. Knowledge concerning functional consequences of many MUTYH germline mutations remains sparse. Most thoroughly investigated are the two most common MUTYH variants, Y179C and G396D, both generating dysfunctional gene products. Phenotypic features of MAP include: development of 10-100 colorectal adenomas, debuting at 46-47 years, often CRC at time of clinical diagnosis, and in some, development of extracolonic manifestations.
Export Options
About this article
Cite this article as:
Poulsen L.M. M. and Bisgaard L. M., MUTYH Associated Polyposis (MAP), Current Genomics 2008; 9 (6) . https://dx.doi.org/10.2174/138920208785699562
DOI https://dx.doi.org/10.2174/138920208785699562 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes
Current Pharmaceutical Design Prognostic Factors after R0 Resection of Colorectal Cancer Liver Metastases: A Systematic Review and Pooled-Analysis
Reviews on Recent Clinical Trials Genetic Molecular Subtypes in Optimizing Personalized Therapy for Metastatic Colorectal Cancer
Current Drug Targets Biomarkers for Colorectal Cancer: Identification Through Proteomics
Current Proteomics 2-(ω-Carboxyethyl)pyrrole Antibody as a New Inhibitor of Tumor Angiogenesis and Growth
Anti-Cancer Agents in Medicinal Chemistry ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Current Medicinal Chemistry Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery
Current Drug Targets Patent Selections:
Recent Patents on Biomarkers Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets Clinical Evidence of Herb-Drug Interactions: A Systematic Review by the Natural Standard Research Collaboration
Current Drug Metabolism The Roles of miR-25 and its Targeted Genes in Development of Human Cancer
MicroRNA Detection of Predictive Markers for Therapeutic Stratification of Salivary Glands Tumors
Current Drug Targets [6]-gingerol as a Cancer Chemopreventive Agent: A Review of Its Activity on Different Steps of the Metastatic Process
Mini-Reviews in Medicinal Chemistry Regulation of KRAS-PAK4 Axis by MicroRNAs in Cancer
Current Pharmaceutical Design Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science Can Systems Biology Understand Pathway Activation? Gene Expression Signatures as Surrogate Markers for Understanding the Complexity of Pathway Activation
Current Genomics Inflammatory Mediators Hold the Key to Dendritic Cell Suppression and Tumor Progression
Current Medicinal Chemistry The Histone Deacetylase SIRT6: At the Crossroads Between Epigenetics, Metabolism and Disease
Current Topics in Medicinal Chemistry Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions
Anti-Cancer Agents in Medicinal Chemistry